Cancilla Daniel, Rettig Michael P, DiPersio John F
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Front Oncol. 2020 Sep 4;10:1672. doi: 10.3389/fonc.2020.01672. eCollection 2020.
The interaction of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) blasts with the bone marrow microenvironment regulates self-renewal, growth signaling, as well as chemotherapy resistance. The chemokine receptor, CXC receptor 4 (CXCR4), with its ligand chemokine ligand 12 (CXCL12), plays a key role in the survival and migration of normal and malignant stem cells to the bone marrow. High expression of CXCR4 on AML and ALL blasts has been shown to be a predictor of poor prognosis for these diseases. Several small molecule inhibitors, short peptides, antibodies, and antibody drug conjugates have been developed for the purposes of more effective targeting and killing of malignant cells expressing CXCR4. In this review we will discuss recent results and strategies in targeting CXCR4 with these agents in patients with AML or ALL.
急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）的原始细胞与骨髓微环境之间的相互作用调节自我更新、生长信号以及化疗耐药性。趋化因子受体CXC受体4（CXCR4）及其配体趋化因子配体12（CXCL12）在正常和恶性干细胞向骨髓的存活和迁移中起关键作用。AML和ALL原始细胞上CXCR4的高表达已被证明是这些疾病预后不良的一个预测指标。为了更有效地靶向和杀死表达CXCR4的恶性细胞，已经开发了几种小分子抑制剂、短肽、抗体和抗体药物偶联物。在这篇综述中，我们将讨论在AML或ALL患者中使用这些药物靶向CXCR4的最新研究结果和策略。
